http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-1247530-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5c24684033fba97d1ad845ce453a57e3 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-10 |
| filingDate | 1985-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1988-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8fb5f691bdf62859f73265494f2402c4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1dfd6c2178081ea53863c024ed7e5a79 |
| publicationDate | 1988-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-1247530-A |
| titleOfInvention | Combination product composed of xanthine derivatives and o-acetylsalicylic acid or its pharmacologically tolerated salts, and its use |
| abstract | Abstract of the Disclosure: A combination product containing A) on the one hand a xanthine derivative of the formula (I) in which one of the radicals R1 and R3 represents a straight-chain alkyl, (.omega.-1)-oxoalkyl or (.omega.-1)-hydroxy-alkyl group having 3 to 8 carbon atoms, and the two other radicals R2 and R3, or R1 and R2 represent straight-chain or branched alkyl groups having 1 to 8 carbon atoms in the position of R1 and R3 and 1 to 4 carbon atoms in the position of R2, the maximum total of carbon atoms in these two alkyl substituents being 10, or of the formula (II) in which R represents an alkyl radical having 1 to 4 carbon atoms, or prodrug forms of the oxoalkylxanthines of the formula I and II or of the hydroxylalkylxanthine of the formula I, or its metabolites, and B) on the other hand O-acetylsalicylic acid or its phar-macologically tolerated salts, C) with or without a pharmaceutical vehicle, for sequential administration in the treatment of disea-ses caused or characterized by impaired constituents of blood, in particular platelets or erythrocytes, but also leukocytes, in such a manner that component A) is released first, and its use in human and veterinary medicine. |
| priorityDate | 1984-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 104.